NCoA-3 Antibody (AX15.3): sc-33671
- NCoA-3 Antibody (AX15.3) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 605-1294 of NCoA-3 of human origin
- recommended for detection of NCoA-3 of human origin by WB, IP, IF and IHC(P)
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for NCoA-3 Antibody (AX15.3) for WB and IHC(P) applications. These reagents are now offered in bundles with NCoA-3 Antibody (AX15.3) (see ordering information below).
QUICK LINKS
NCoA-3 Antibody (AX15.3) is a mouse monoclonal IgG1 antibody that detects NCoA-3 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. NCoA-3, also known as RAC3, ACTR, AIB-1, and p/CIP, plays a crucial role as a transcriptional coactivator that interacts with steroid hormone receptors, thereby influencing gene expression in response to hormonal signals. NCoA-3 (AX15.3) antibody has proven particularly significant in cancer biology research, as NCoA-3 exhibits elevated expression levels in estrogen receptor-positive ovarian and breast cancers, underscoring its potential as a biomarker for these malignancies. NCoA-3′s ability to modulate transcriptional activity through interactions with various nuclear receptors and other transcription factors highlights its importance in regulating cellular processes such as proliferation and differentiation. Anti-NCoA-3 antibody (AX15.3) enables researchers to gain valuable insights into hormone action mechanisms and NCoA-3′s role in cancer progression, making this antibody an essential tool for studies in molecular biology and oncology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
NCoA-3 Antibody (AX15.3) References:
- Essential roles for the nuclear receptor coactivator Ncoa3 in pluripotency. | Percharde, M. and Azuara, V. 2013. Cell Cycle. 12: 195-6. PMID: 23287469
- NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. | Kumar, S., et al. 2015. Oncogene. 34: 4879-89. PMID: 25531332
- NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2α-ATF4 signalling in breast cancer. | Gupta, A., et al. 2016. Oncogene. 35: 5860-5871. PMID: 27109102
- MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation. | Li, Y., et al. 2018. Mol Oncol. 12: 391-405. PMID: 29360267
- NCOA3 Loss Disrupts Molecular Signature of Chondrocytes and Promotes Posttraumatic Osteoarthritis Progression. | Zhang, B., et al. 2018. Cell Physiol Biochem. 49: 2396-2413. PMID: 30261507
- Targeting the NCOA3-SP1-TERT axis for tumor growth in hepatocellular carcinoma. | Li, W., et al. 2020. Cell Death Dis. 11: 1011. PMID: 33239622
- NCOA3 identified as a new candidate to explain autosomal dominant progressive hearing loss. | Salazar-Silva, R., et al. 2021. Hum Mol Genet. 29: 3691-3705. PMID: 33326993
- Chimeric RNA TNNI2-ACTA1-V1 Regulates Cell Proliferation by Regulating the Expression of NCOA3. | Liu, D., et al. 2022. Front Vet Sci. 9: 895190. PMID: 35898549
- NCoA3 upregulation in breast cancer‑associated adipocytes elicits an inflammatory profile. | Lira, MC., et al. 2023. Oncol Rep. 49: PMID: 37026525
- NCOA3 knockdown delays human embryo development. | Wu, Z., et al. 2024. Heliyon. 10: e37639. PMID: 39315150
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NCoA-3 Antibody (AX15.3) | sc-33671 | 200 µg/ml | $322.00 | |||
NCoA-3 Antibody (AX15.3): m-IgG Fc BP-HRP Bundle | sc-538929 | 200 µg Ab; 10 µg BP | $361.00 | |||
NCoA-3 Antibody (AX15.3): m-IgG1 BP-HRP Bundle | sc-541159 | 200 µg Ab; 20 µg BP | $361.00 |